These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. Kurland L, Hallberg P, Melhus H, Liljedahl U, Hashemi N, Syvänen AC, Lind L, Kahan T. Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745 [Abstract] [Full Text] [Related]
5. Interactive Effect of the KCNJ11 Ile337Val Polymorphism and Cigarette Smoking on the Antihypertensive Response to Irbesartan in Chinese Hypertensive Patients. Jiang S, Venners SA, Hsu YH, Weinstock J, Wang B, Xing H, Wang X, Xu X. Am J Hypertens; 2016 May; 29(5):553-9. PubMed ID: 26304961 [Abstract] [Full Text] [Related]
7. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients. Chen G, Jiang S, Mao G, Zhang S, Hong X, Tang G, Li Z, Liu X, Zhang Y, Xing H, Wang B, Yu Y, Xu X. Methods Find Exp Clin Pharmacol; 2006 May; 28(1):19-24. PubMed ID: 16541193 [Abstract] [Full Text] [Related]
8. Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension. Zhang S, Liu P, Jiang S, Hong X, Xing H, Xu X. Methods Find Exp Clin Pharmacol; 2005 Apr; 27(3):173-8. PubMed ID: 15834449 [Abstract] [Full Text] [Related]
9. Renin-angiotensin-aldosterone system gene polymorphisms and antihypertensive response to irbesartan in Chinese hypertensives. Liu H, Zhang S, Jiang S, Mao G, Hong X, Yu Y, Zhang Y, Tang G, Xing H, Xu X. Methods Find Exp Clin Pharmacol; 2008 May; 30(4):307-12. PubMed ID: 18773126 [Abstract] [Full Text] [Related]
12. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L. J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301 [Abstract] [Full Text] [Related]
14. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. Lewin AJ, Weir MR. Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594 [Abstract] [Full Text] [Related]
16. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R, COmparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension (COSIMA) Investigators. Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286 [Abstract] [Full Text] [Related]
18. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension. Neutel JM, Germino FW, Smith D. J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487 [Abstract] [Full Text] [Related]
19. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. Derosa G, Cicero AF, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Fassi R, Fogari R. Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283 [Abstract] [Full Text] [Related]